



## Novel method for measurement of heparin anticoagulant activity using SPR



Jing Zhao<sup>a,d</sup>, Xinyue Liu<sup>a</sup>, Anju Malhotra<sup>b</sup>, Quanhong Li<sup>d</sup>, Fuming Zhang<sup>b,\*</sup>, Robert J. Linhardt<sup>a,b,c,\*\*</sup>

<sup>a</sup> Department of Chemistry and Chemical Biology, Troy, NY 12180, USA

<sup>b</sup> Department of Chemical and Biological Engineering, Troy, NY 12180, USA

<sup>c</sup> Departments of Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA

<sup>d</sup> College of Food Science & Nutritional Engineering, China Agricultural University, Beijing 100083, China

### ARTICLE INFO

#### Article history:

Received 7 November 2016

Received in revised form

16 January 2017

Accepted 14 March 2017

Available online 18 March 2017

#### Keywords:

Anticoagulant activity

Heparin

SPR

Antithrombin III

### ABSTRACT

A novel method has been developed for the easy measurement of heparin's anticoagulant activity using surface plasmon resonance. The anticoagulant activity of target heparin was evaluated by measuring the competitive antithrombin III binding of analyte heparin in the solution phase and USP heparin immobilized on chip surface. Heparins, obtained from different animal sources, and low molecular weight heparins were analyzed. The results were reproducible and correlated well with the results of chromogenic assays (correlation coefficient  $r = 0.98$  for anti-Xa and  $r = 0.94$  for anti-IIa). This protocol provides many advantages, significantly minimizing time, cost and the complications of chromogenic assay methods.

© 2017 Elsevier Inc. All rights reserved.

Heparin is a linear, polydisperse, anionic, and highly sulfated polysaccharide derived from animal tissues [1]. Heparin-based anticoagulant drugs have been widely used clinically since 1935. However, an international heparin contamination crisis occurred in 2007–2008 resulting in a rising concern about the quality of heparin. Since then, improved assays for the anticoagulant activities of low molecular weight (LMW) heparins, biosynthetic heparins, bioengineered heparins, and heparins extracted from the organs of different animals have been developed [2–5]. With the development of new heparin-based drugs, novel methods for the quick, easy and accurate measurement of anticoagulant activity are needed to ensure quality control of these heparin products.

The anticoagulant activity of heparin is primarily mediated through its binding and regulation of antithrombin III (AT), which is a serine protease inhibitor that inactivates various activated coagulation serine proteases, including factors IXa, Xa, TF-VIIa complex, and thrombin (factor IIa) [6,7]. The ability of AT to inhibit serine

proteases is markedly enhanced in the presence of heparin [8]. Accordingly, the interaction between heparin and AT is a crucial step in the anticoagulation process, which is the key step for the measurement of anticoagulant activity of heparin.

The chromogenic methods for anti-Xa and anti-IIa assay using commercial kits (i.e., HYPHEN BioMed) involve a two-step chromogenic method based on the inhibition of a constant, excess amount of factor Xa/IIa, by the tested heparin in presence of exogenous AT (stage 1), and the hydrolysis of factor Xa/IIa-specific chromogenic substrate, by residual factor Xa/IIa (stage 2). The *p*-nitroaniline (pNA) chromogen is then released from the substrate and the released amount is related to the residual factor Xa/IIa activity. The reactions for the two-step chromogenic method factor Xa activity are:

Stage 1:  $\text{Hep.} + \text{AT} \rightarrow [\text{AT Hep.}]$ ;

Stage 2:  $[\text{AT Hep.}] + [\text{FXa (excess)}] \rightarrow [\text{FXa-AT-Hep.}] + [\text{residual FXa}]$ ;

$[\text{residual FXa}] + \text{Substrate} \rightarrow \text{Peptide} + \text{pNA (A405 nm)}$

There is an inverse relationship between the concentration of heparin and color development, measured at 405 nm. These

\* Corresponding author.

\*\* Corresponding author. Department of Chemistry and Chemical Biology, Troy, NY 12180, USA.

E-mail addresses: [zhangf2@rpi.edu](mailto:zhangf2@rpi.edu) (F. Zhang), [linhar@rpi.edu](mailto:linhar@rpi.edu) (R.J. Linhardt).


chromogenic methods require a high level of skill, are time consuming, and their accuracy can be impacted by the variable quality of available reagents.

Surface plasmon resonance (SPR), a rapidly developing technique for research on molecular interactions, is label-free, real-time, medium-throughput and requires only small quantities of reagents. It uses an optical method to measure the change in refractive index of the medium close to a metal surface to monitor the binding of analyte molecules to receptor molecules, which are immobilized on the metal surface [9]. We found that the binding between heparin and AT is easy to measure using SPR (Biacore 3000, GE healthcare, Uppsala, Sweden) and this can be developed as a new method to quickly evaluate the anticoagulant activity of heparin.

Our SPR method is mainly based on a competitive effect between standard USP heparin that is biotinylated and immobilized on the SA chip (GE healthcare, Uppsala, Sweden) and a heparin sample that is pre-mixed with AT in the solution (Fig. 1 A). The biotinylated heparin was synthesized by reacting sulfo-*N*-hydroxysuccinimide long-chain biotin (Thermo Scientific, Waltham, MA) with the free amino groups of unsubstituted glucosamine residues in the heparin chain following a published procedure [10]. Once the heparin-binding sites of AT are occupied by heparin in the solution phase, AT binding to the surface-immobilized heparin should decrease, resulting in a reduction in the RU of the SPR signal. This well-established competition SPR method has been previously used in many studies for characterizing heparin/protein interaction [11–13]. The SPR method first requires the immobilization of standard USP heparin on a streptavidin (SA) chip following the manufacturer's protocol. In brief, a 20  $\mu$ L solution of the heparin-

biotin conjugate in HBS-EP running buffer [0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005% surfactant P20, (pH 7.4)] is injected over the flow cell of a SA chip at a flow rate 10  $\mu$ L/min. Successful immobilization of heparin can be confirmed by a ~200 resonance unit (RU) increase in the sensor chip. USP heparin was immobilized to the three flow cells of an SA chip and one flow cell, serving as a control, was prepared by a 20  $\mu$ L injection with a saturated solution of biotin. Different dilutions of heparin analyte, having different total activities, were pre-mixed with AT solution just prior to injection. At the end of the each sample injection, the sensor surface was regenerated by injecting 30  $\mu$ L of 2 M NaCl. The response was monitored as a function of time (sensorgram) at 25  $^{\circ}$ C. AT solution without heparin was flowed across the chip's surface as a control experiment. The competitive effect of different heparin samples was measured through the decrease of the RU resulting from the addition of heparin into AT solution (Fig. 1B, C and D). This protocol requires only standard USP heparin as reference and AT as reactant and does not require the various chemical and protein reagents used in chromogenic methods. In addition, it is much easier to perform SPR than a chromogenic assay, which depends on sequential addition of reagents and the strict control of reaction times and environmental conditions.

In this study, heparin samples from several animal sources: porcine intestinal heparins from Scientific Protein Laboratories (SPL, Madison, WI), bovine lung heparin (BL1, provided by Dr. J. Fareed in Loyola University) and LMW heparins (LMW1, from Sandoz) were determined based on the SPR method. The results were then compared with activities measured by chromogenic methods, using anti-Xa and anti-IIa kit of HYPHEN BioMed (West Chester, OH). SPR sensorgrams from different dilutions of the



**Fig. 1.** A. Diagram of SPR solution competition experiment for anticoagulant activity measurement of heparin samples. **B to D:** SPR sensorgrams of AT binding to heparin surface competing with different heparin samples. **B:** USP heparin; **C:** LMW heparin; **D:** bovine lung heparin. The concentration of AT was 62.5 nM. Heparin concentrations in solution (from top to bottom) were 0, 3.13, 6.25, 12.5, 25, and 50  $\mu$ g/mL, respectively.

Download English Version:

<https://daneshyari.com/en/article/5131622>

Download Persian Version:

<https://daneshyari.com/article/5131622>

[Daneshyari.com](https://daneshyari.com)